JP5421098B2 - トリメブチン及びｎ−脱メチル化トリメブチンの塩類 - Google Patents

トリメブチン及びｎ−脱メチル化トリメブチンの塩類 Download PDF

Info

Publication number
JP5421098B2
JP5421098B2 JP2009513524A JP2009513524A JP5421098B2 JP 5421098 B2 JP5421098 B2 JP 5421098B2 JP 2009513524 A JP2009513524 A JP 2009513524A JP 2009513524 A JP2009513524 A JP 2009513524A JP 5421098 B2 JP5421098 B2 JP 5421098B2
Authority
JP
Japan
Prior art keywords
compound
trimebutine
compounds
demethylated
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2009513524A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009539777A (ja
JP2009539777A5 (https=
Inventor
ワレス、ジョン、エル．
シリノ、ギウゼッペ
サンタガーダ、ビンセンゾ
カリエンド、ギウゼッペ
Original Assignee
ジーアイケア ファーマ インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジーアイケア ファーマ インク． filed Critical ジーアイケア ファーマ インク．
Publication of JP2009539777A publication Critical patent/JP2009539777A/ja
Publication of JP2009539777A5 publication Critical patent/JP2009539777A5/ja
Application granted granted Critical
Publication of JP5421098B2 publication Critical patent/JP5421098B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C219/02—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C219/04—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C219/14—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the hydroxy groups esterified by a carboxylic acid having the esterifying carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/30—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to nitro or nitroso groups
    • C07C279/32—N-nitroguanidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C219/02—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C219/02—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C219/20—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated
    • C07C219/22—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C327/00—Thiocarboxylic acids
    • C07C327/38—Amides of thiocarboxylic acids
    • C07C327/48—Amides of thiocarboxylic acids having carbon atoms of thiocarboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D339/00—Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
    • C07D339/02—Five-membered rings
    • C07D339/04—Five-membered rings having the hetero atoms in positions 1 and 2, e.g. lipoic acid

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2009513524A 2006-06-06 2007-06-06 トリメブチン及びｎ−脱メチル化トリメブチンの塩類 Expired - Fee Related JP5421098B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US80406706P 2006-06-06 2006-06-06
US60/804,067 2006-06-06
PCT/CA2007/001008 WO2007140611A1 (en) 2006-06-06 2007-06-06 Salts of trimebutine and n-desmethyl trimebutine

Publications (3)

Publication Number Publication Date
JP2009539777A JP2009539777A (ja) 2009-11-19
JP2009539777A5 JP2009539777A5 (https=) 2010-12-24
JP5421098B2 true JP5421098B2 (ja) 2014-02-19

Family

ID=38801016

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009513524A Expired - Fee Related JP5421098B2 (ja) 2006-06-06 2007-06-06 トリメブチン及びｎ−脱メチル化トリメブチンの塩類

Country Status (10)

Country Link
US (2) US20110144188A1 (https=)
EP (1) EP2024323B1 (https=)
JP (1) JP5421098B2 (https=)
KR (1) KR20090021346A (https=)
CN (1) CN101489986A (https=)
AU (1) AU2007257174B2 (https=)
BR (1) BRPI0712417A2 (https=)
CA (1) CA2653869A1 (https=)
RU (1) RU2008152751A (https=)
WO (1) WO2007140611A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7741359B2 (en) * 2005-05-27 2010-06-22 Antibe Therapeutics Inc. Hydrogen sulfide derivatives of non-steroidal anti-inflammatory drugs
US7932286B2 (en) * 2007-07-31 2011-04-26 Martin Francois Method for treating colonic viscerosensitivity and spasticity
FR2927076B1 (fr) * 2008-01-31 2010-03-26 Oroxcell Derives de 2-amino-2-phenyl-alkanol, leur preparation et les compositions pharmaceutiques qui les contiennent
EP2744487B1 (en) 2011-08-15 2016-10-05 Research Foundation Of The City University Of New York No- and h2s- releasing compounds
IN2014DN08379A (https=) * 2012-03-12 2015-05-08 Gicare Pharma Inc
WO2016044951A1 (en) * 2014-09-25 2016-03-31 The Hospital For Sick Children Compositions and methods for enhancing hair growth, promoting skin regeneration, and wound healing
RU2752086C1 (ru) 2020-04-27 2021-07-22 Общество С Ограниченной Ответственностью "Валента-Интеллект" Новое соединение [2-(диметиламино)-2-фенилбутил]-3,4,5-триметоксибензоата 4-метил-2н-хромен-2-он-7-илсульфат и его применение
CN114916547B (zh) * 2021-12-06 2024-11-15 南京天秾生物技术有限公司 2,6-二氨基-3-甲基己酸作为植物免疫诱抗剂的应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2460919A1 (fr) * 1979-07-11 1981-01-30 Prod Synthese Ste Indle Amino-ethers oxydes, leur procede de preparation et leur application en therapeutique
JPS57500432A (https=) * 1980-03-20 1982-03-11
US4412992A (en) * 1980-07-21 1983-11-01 Biorex Laboratories Limited 2-Hydroxy-5-phenylazobenzoic acid derivatives and method of treating ulcerative colitis therewith
US4440763A (en) * 1981-03-18 1984-04-03 Block Drug Company, Inc. Use of 4-aminosalicyclic acid as an anti-inflammatory agent
ZA825384B (en) * 1981-07-31 1983-05-25 Tillott J B Ltd Orally administrable pharmaceutical compositions
US4751221A (en) * 1985-10-18 1988-06-14 Sloan-Kettering Institute For Cancer Research 2-fluoro-arabinofuranosyl purine nucleosides
US5245080A (en) * 1989-02-20 1993-09-14 Jouveinal Sa (+)-1-[(3,4,5-trimethoxy)-benzyloxymethyl]-1-phenyl-N,N-dimethyl-N-propylamine, process for preparing it and its therapeutical use
US5811547A (en) * 1992-10-14 1998-09-22 Nippon Shinyaju Co., Ltd. Method for inducing crystalline state transition in medicinal substance
CA2204747C (en) 1995-09-08 2009-05-05 Elena Carceller New azo derivatives of 5-aminosalicylic acid
SE9700934D0 (sv) * 1997-03-14 1997-03-14 Astra Ab New formulation
WO1998048826A1 (en) * 1997-04-30 1998-11-05 Northwestern University Inhibition of nitric oxide synthase by amino acids and dipeptides
SV2001000242A (es) * 1999-12-23 2001-10-25 Warner Lambert Co Combinacion de trimebutina con un analgesico derivado del opio
EP1110549A1 (en) * 1999-12-23 2001-06-27 Warner-Lambert Company Use of trimebutine for treating pain
EP1296943A1 (fr) * 2000-05-05 2003-04-02 Societe De Conseils De Recherches Et D'applications Scientifiques S.A. (S.C.R.A.S.) Derives d'aminoacides et leur application a titre de medicaments
US6602915B2 (en) * 2000-07-27 2003-08-05 Rutgers, The State University Of New Jersey Therapeutic azo-compounds for drug delivery
AU2001285489A1 (en) * 2000-08-29 2002-03-13 Nobex Corporation 5-ASA derivatives having anti-inflammatory and antibiotic activity and methods of treating diseases therewith
US6986901B2 (en) * 2002-07-15 2006-01-17 Warner-Lambert Company Llc Gastrointestinal compositions
JP2005533101A (ja) * 2002-07-10 2005-11-04 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー アロステリック阻害剤又はマトリックス金属タンパク質分解酵素−１３の、セレコキシブでもバルデコキシブでもないシクロオキシゲナーゼ−２の選択的阻害剤との組合せ物
US20040213842A1 (en) * 2003-01-30 2004-10-28 Dynogen Pharmaceuticals, Inc. Methods of treating gastrointestinal tract disorders using sodium channel modulators
EP1645288A1 (en) 2004-10-07 2006-04-12 CTG Pharma S.r.l. New nuclear transcription factors regulators

Also Published As

Publication number Publication date
US20070275905A1 (en) 2007-11-29
EP2024323B1 (en) 2013-03-27
EP2024323A1 (en) 2009-02-18
EP2024323A4 (en) 2010-07-28
WO2007140611A1 (en) 2007-12-13
AU2007257174B2 (en) 2012-07-12
KR20090021346A (ko) 2009-03-03
BRPI0712417A2 (pt) 2012-09-04
JP2009539777A (ja) 2009-11-19
RU2008152751A (ru) 2010-07-20
US20110144188A1 (en) 2011-06-16
AU2007257174A1 (en) 2007-12-13
CN101489986A (zh) 2009-07-22
US7666907B2 (en) 2010-02-23
CA2653869A1 (en) 2007-12-13

Similar Documents

Publication Publication Date Title
JP5421098B2 (ja) トリメブチン及びｎ−脱メチル化トリメブチンの塩類
JP5221341B2 (ja) ４−または５−アミノサリチル酸誘導体
TWI337994B (en) Prostaglandin derivatives
US9029420B2 (en) Agomelatine and pharmaceutical compositions thereof
CN102850317B (zh) 一种取代桂皮酰胺衍生物、制备方法及其应用
US20130059801A1 (en) Fatty acid amides, compositions and methods of use
CN101417967A (zh) 组蛋白去乙酰酶抑制剂、其组合物及其应用
CN101337984A (zh) 熊果烷型五环三萜氨基酸衍生物、其制备方法及其医药用途
CN115181154B (zh) Pyxinol酰胺衍生物及其制备方法以及在药物领域中的应用
JP2009539777A5 (https=)
RU2346933C2 (ru) Соединение, обладающее действием против hcv, и способ его получения
US20170073305A1 (en) Fatty acid amides, compositions and methods of use
EP1357910B1 (en) Method for preventing and treating visceral pain and gastrointestinal disorders
US9193673B2 (en) Derivatives of mesalazine, process of their preparation and their use in the treatment of intestinal inflammatory diseases
CN102504005B (zh) 一类具有新型结构的化合物及其制备方法和用途
US20250026781A1 (en) Prodrugs of Neurosteroid Analogs and Uses Thereof
JP2022542183A (ja) 肛門及び直腸の障害の処置のための組成物及び方法
CN104892449A (zh) 一种精胺类似物及其药用盐的制备方法和用途
WO2017185261A1 (zh) 莫沙必利的活性代谢物及其制备方法和用途
AU2004212612A1 (en) Method for preventing and treating visceral pain and gastrointestinal disorders
HK1191322A (zh) 一种取代桂皮醯胺衍生物、制备方法及其应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100605

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100605

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101102

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20120309

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20120309

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20121030

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121106

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130206

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130214

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130507

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20131022

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20131121

LAPS Cancellation because of no payment of annual fees